Compare AMTD & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTD | PYPD |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | France | Israel |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.2M | 77.4M |
| IPO Year | 2019 | 2014 |
| Metric | AMTD | PYPD |
|---|---|---|
| Price | $1.04 | $4.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 28.1K | ★ 40.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $2.30 |
| 52 Week High | $1.65 | $5.12 |
| Indicator | AMTD | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 61.25 | 48.05 |
| Support Level | $0.93 | $4.26 |
| Resistance Level | $1.08 | $4.38 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 78.67 | 61.63 |
AMTD IDEA Group is a financial institution operating in five business segments: The capital market solutions segment assists customers in raising funds through equity and debt financing, private placements, and debt issuances. The digital solutions and other services segment provides institutional and corporate clients with paid access to enhance investor communication and relations, corporate communication also provides digital financial solution services. The Media and entertainment segment offers print and digital advertising campaigns, licensing, and marketing services including branded content, video production. The hotel operations, hospitality, and VIP services segment engages in hotel investments, hotel operations, hospitality, and VIP services; and Strategic investment segment.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.